Skip to product information
Request a Quote
Helicobacter Pylori Selective Agar Base | Ausamics
$37.00 AUD
Selective Culture Medium · Clinical Microbiology · Gastroenterology
Helicobacter pylori Selective Medium Base
Columbia Blood Agar Base + VCTA Selective Supplement
PC2 Pathogen Culture Microaerophilic IARC Group I Pathogen Vancomycin · Trimethoprim · Cefsulodin · Amphotericin B
AuSaMicS
Life Science™
Cat No.
AS-1249
Base Medium
Columbia Blood Agar
Final pH
7.3 ± 0.2
Atmosphere
Microaerophilic
Incubation
37–42 °C / 3–7 d
Overview
Helicobacter pylori Selective Medium Base is a specialised culture medium for the isolation and cultivation of Helicobacter pylori, a microaerophilic Gram-negative spiral bacterium and the primary causative agent of chronic active gastritis, peptic ulcer disease, and gastric adenocarcinoma. Classified as an IARC Group I carcinogen, H. pylori colonises the human gastric mucosa and requires enriched, highly selective conditions for successful primary isolation.
The base medium is Columbia Blood Agar supplemented with 5–10% defibrinated sheep blood (providing haemin, NAD, and growth factors) and a four-antibiotic selective cocktail: vancomycin (Gram-positive suppression), trimethoprim (enteric flora), cefsulodin (anti-Pseudomonas), and amphotericin B (antifungal). H. pylori is intrinsically resistant to all four antibiotics at concentrations used, permitting preferential recovery from complex clinical specimens.
Applications
Primary Isolation
Gold standard culture from gastric biopsy (antrum, corpus, fundus), gastric brushings, and gastric juice specimens for diagnosis and AST.
Antibiotic Sensitivity
Culture-based susceptibility testing (E-test / disk diffusion) for clarithromycin, metronidazole, and levofloxacin resistance profiling per Maastricht V guidelines.
Research & QC
In vitro pathogenesis studies, eradication confirmation cultures, and proficiency testing for NATA / ISO 17025-accredited laboratories.
Selective Antibiotic Supplement (VCTA)
Vancomycin
Suppresses Gram-positive bacteria
~10 mg/L · Glycopeptide · Cell wall inhibition
Trimethoprim
Suppresses enteric Gram-negative bacilli
~5 mg/L · DHFR inhibitor · Folate pathway
Cefsulodin
Inhibits Pseudomonas aeruginosa
~5 mg/L · Beta-lactam · Cell wall inhibition
Amphotericin B
Inhibits yeasts and moulds
~2 mg/L · Polyene · Ergosterol binding
H. pylori is intrinsically resistant to all four antibiotics at concentrations used, enabling highly selective recovery from heavily contaminated gastric specimens.
Colony Identification & Confirmation
| Colony morphology | Small (0.5–2 mm), circular, convex, translucent to grey, smooth; non-haemolytic (gamma) |
| Urease test | Strongly positive — rapid urease colour change within 1–4 hours |
| Oxidase test | Positive |
| Catalase test | Positive |
| Gram stain | Gram-negative spiral / curved rods; S-shaped or seagull morphology |
| Motility | Positive — corkscrew motility by dark-field or phase-contrast microscopy |
| Molecular confirmation | 16S rRNA PCR or species-specific PCR for definitive identification |
Incubation Requirements
Standard
37–42 °C
3–7 days · Microaerophilic atmosphere
5–10% CO², 5–10% O², balance N²
5–10% CO², 5–10% O², balance N²
Critical Requirements
≥ 95% RH
High humidity essential — prevent desiccation
Use CampyPak or equivalent gas generator
Use CampyPak or equivalent gas generator
Aerobic and anaerobic conditions are NOT suitable — H. pylori requires strict microaerophilic atmosphere for growth. Standard CO² incubators are insufficient without O² control.
Storage & Shelf Life
| Dehydrated Base | 15–30 °C, dry place, tightly closed, protected from light and moisture |
| Prepared Plates | 2–8 °C, sealed in plastic bag — use within 2 weeks of preparation |
| After Opening | Reseal immediately; use desiccant sachet if humidity > 60% RH |
| Do Not Use If | Powder shows caking or discolouration; plates show contamination, drying, or colour change |
AuSaMicS Pty Ltd (ABN 56 676 640 467) warrants that this product meets stated specifications at time of manufacture. For laboratory use only. Not intended for human, animal, food, feed, or pharmaceutical use. · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
Product Identification
| Product Name | H. pylori Selective Medium Base |
| Catalog No. | AS-1249 |
| Lot No. | HPS260301 |
| Mfg. Date | March 2026 |
| Retest Date | March 2028 |
| Grade | Microbiological / Selective |
| Base Medium | Columbia Blood Agar Base |
Physical Properties
| Appearance (powder) | Homogeneous; light beige to pale pink |
| Appearance (prepared) | Opaque, red-brown gel (with 5% sheep blood) |
| pH (prepared, 25 °C) | 7.3 ± 0.2 |
| Agar gel / melt | Gels ~32–34 °C / Melts ~84–86 °C |
| Loss on Drying | ≤ 7.0% w/w |
| Haemolysis | Gamma (non-haemolytic) for H. pylori |
Base Medium Composition per Litre (Columbia Base)
| Component | Function | Amount (g/L) |
|---|---|---|
| Peptone (mixed — casein/meat/heart) | Nitrogen, amino acids — supports fastidious organisms | 23.00 |
| Cornstarch (soluble) | Carbon source + protective agent for organism viability | 1.00 |
| Sodium Chloride | Osmotic balance | 5.00 |
| Agar (bacteriological grade) | Solidifying agent | 10.00 |
| TOTAL (base powder per litre) | 39.00 | |
| Defibrinated sheep blood | Growth factors (haemin, NAD), haemolysis indicator — ADD AFTER AUTOCLAVING | 5–10% v/v |
Selective Antibiotic Supplement
| Antibiotic | Typical Concentration | Target Organisms Suppressed | Mechanism |
|---|---|---|---|
| Vancomycin | 10 mg/L | Gram-positive bacteria | Cell wall synthesis (glycopeptide) |
| Trimethoprim | 5 mg/L | Enteric Gram-negative bacilli | DHFR inhibition |
| Cefsulodin | 5 mg/L | Pseudomonas aeruginosa | Beta-lactam / cell wall |
| Amphotericin B | 2 mg/L | Yeasts and moulds | Ergosterol binding |
Preparation Protocol
- 1Suspend 39 g of dehydrated Columbia base in 1 L of purified water.
- 2Heat with agitation until completely dissolved. Bring to a rolling boil for 1 minute.
- 3Autoclave at 121 °C (15 psi) for 15 minutes.
- 4Cool to exactly 45–50 °C. Critical: above 50 °C will lyse blood cells.
- 5Add 5–10% v/v defibrinated sheep blood (pre-warmed to 45 °C) aseptically. Mix gently — avoid frothing.
- 6Add antibiotic selective supplement aseptically per manufacturer's instructions. Mix gently.
- 7Pour 15–20 mL per 90 mm plate under laminar flow. Allow to solidify.
- 8Dry at 37 °C for 30–45 min. Store at 2–8 °C in sealed bags. Use within 2 weeks.
Quality Control Specifications
| Parameter | Specification | Method |
|---|---|---|
| Appearance (powder) | Homogeneous; light beige to pale pink | Visual inspection |
| pH (prepared, 25 °C) | 7.1 – 7.5 | Potentiometry |
| Growth — H. pylori ATCC 43504 | Good growth; translucent colonies at day 3–5 (37 °C, microaerophilic) | Culture test |
| Inhibition — E. coli ATCC 25922 | Complete / ≥ 99% inhibition | Selectivity test |
| Inhibition — C. albicans ATCC 10231 | Complete inhibition | Antifungal selectivity |
| Haemolysis pattern | Gamma (non-haemolytic) for H. pylori | Visual — plate check |
| Sterility | No growth at 14 days (aerobic, 30–35 °C) | Incubation check |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
Safety Data Sheet — GHS Format (Australian WHS Regulations 2017)
Issue Date: March 2026 · Rev: 1.0 · Prepared in accordance with WHS Regulations and GHS 7th Revision.
Issue Date: March 2026 · Rev: 1.0 · Prepared in accordance with WHS Regulations and GHS 7th Revision.
Biological Hazard: This medium is designed to culture H. pylori — an IARC Group I carcinogen and Risk Group 2 human pathogen. PC2 containment required. All prepared medium and cultures must be treated as biohazardous. Follow AS/NZS 2243.3:2010.
Reproductive Toxicant: Trimethoprim (H360) — pregnant workers must avoid handling.
Reproductive Toxicant: Trimethoprim (H360) — pregnant workers must avoid handling.
Section 1 — Identification
| Product Name | Helicobacter pylori Selective Medium Base |
| Catalog No. | AS-1249 |
| Intended Use | Selective microbiological culture medium — PC2 laboratory use only |
| Supplier | AuSaMicS Pty Ltd, 31 Longview CT, Thomastown VIC 3074, Australia |
| Phone / Emergency | +61 412 520 598 · Poisons Centre: 13 11 26 (24h) |
| Email / Web | support@ausamics.com · www.ausamics.com.au |
Section 2 — Hazard Identification
| GHS Classification | H315 (skin irritation) · H319 (eye irritation) · H360 (reproductive toxicant Cat.2 — trimethoprim) · H335 (respiratory irritation) |
| Signal Word | WARNING |
| Precautionary | P201 · P260 · P264 · P280 · P308+P313 · P501 |
| Biological Hazard | PC2 required. H. pylori = IARC Group I carcinogen · Risk Group 2. All cultures biohazardous. |
Section 3 — Composition
| Component | CAS No. | Proportion (w/w) | GHS Classification |
|---|---|---|---|
| Agar (bacteriological) | 9002-18-0 | ~25.6% | Not classified |
| Peptone (mixed) | — | ~58.9% | Not classified |
| Cornstarch | 9005-25-8 | ~2.6% | Not classified |
| Sodium Chloride | 7647-14-5 | ~12.8% | Not classified |
| Vancomycin HCl | 1404-93-9 | < 0.1% | H315 · H319 · H335 |
| Trimethoprim | 738-70-5 | < 0.1% | H360 (Cat. 2) · H315 · H319 |
| Cefsulodin sodium | 52152-93-9 | < 0.1% | H315 · H317 · H319 |
| Amphotericin B | 1397-89-3 | < 0.1% | H315 · H317 · H319 · H335 |
| Defibrinated sheep blood | — | 5–10% v/v (supplement) | Biological material — PC2 |
Sections 4–8 — First Aid, Fire, Spill, Handling, PPE
| Inhalation | Remove to fresh air. Trimethoprim: avoid repeated inhalation (reproductive toxicant). Seek advice if symptomatic. |
| Skin Contact | Wash with soap and water ≥ 15 min. Remove contaminated clothing. Seek advice if sensitisation reaction (cefsulodin / amphotericin B). |
| Eye Contact | Rinse with copious water ≥ 15 min, holding eyelids open. Seek prompt medical attention. |
| Ingestion | Do not induce vomiting. Rinse mouth. Seek medical advice. Show SDS to physician. |
| Biological Spill | BIOHAZARD: Apply 1% hypochlorite or 70% ethanol. Contact time ≥ 30 min. Autoclave all waste. Report per institutional biosafety policy. |
| Flash Point | Not applicable (non-flammable powder) |
| Engineering Controls | Class II BSC mandatory for all culture work. Local exhaust ventilation when weighing powder. |
| Respiratory PPE | P2 mask when generating dust; PAPR for high-risk procedures |
| Hand Protection | Nitrile gloves — double-glove for culture work |
| Pregnancy Warning | Trimethoprim H360: Pregnant workers or those planning pregnancy MUST avoid handling. Seek occupational health advice. |
Sections 9–12 — Properties, Stability, Toxicology, Ecology
| Physical State | Solid (powder) / Opaque gel (prepared with blood) |
| pH (prepared) | 7.3 ± 0.2 |
| Reproductive Toxicity | H360 — Trimethoprim: suspected reproductive toxicant (Category 2) |
| Skin/Eye Irritation | H315 / H319 — antibiotic components |
| Sensitisation | Cefsulodin (beta-lactam cross-reaction risk); amphotericin B sensitisation possible |
| Biological Hazard | H. pylori: IARC Group I carcinogen; Risk Group 2 organism |
| Aquatic Toxicity | Amphotericin B and cefsulodin — potentially toxic to aquatic organisms; prevent discharge |
| Antibiotic Resistance | Prevent environmental discharge — antibiotic resistance gene dissemination risk |
Sections 13–15 — Disposal, Transport, Regulatory
| Waste Classification | Clinical / biohazardous waste — contains antibiotic agents and is designed for pathogen culture |
| Prepared Medium (used) | Autoclave 134 °C / 18 min or 121 °C / 30 min. Dispose as clinical waste per AS/NZS 3816:1998. |
| Sharps | Approved sharps containers. Do not recap needles. |
| Transport (cultures) | UN 3373 — Biological Substance Category B. IATA P650 packing instructions apply. |
| AICS / SUSMP | All components on AICS. Trimethoprim: Schedule 4; Amphotericin B: Schedule 4 — supplied for laboratory use only. |
| Biosafety Level | H. pylori: Risk Group 2 per AS/NZS 2243.3:2010 — PC2 containment required |
| WHS Regulations | Hazardous chemicals (trimethoprim H360, antibiotics) + biological pathogen — WHS Regulations 2017 apply |
AuSaMicS Pty Ltd (ABN 56 676 640 467) · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
This SDS is prepared in accordance with Australian WHS Regulations and GHS (7th Rev.). For PC2 laboratory use only.
This SDS is prepared in accordance with Australian WHS Regulations and GHS (7th Rev.). For PC2 laboratory use only.
Product Details
| Product Name | H. pylori Selective Medium Base |
| Catalog No. | AS-1249 |
| Lot No. | HPS260301 |
| Mfg. Date | March 2026 |
| Retest Date | March 2028 |
| Grade | Microbiological / Selective |
| Base | Columbia Blood Agar + VCTA Supplement |
Document Information
| COA No. | COA-AS-1249-L001 |
| Issue Date | March 2026 |
| Issued By | AuSaMicS Quality Control |
| Test Ref. | In-house / ATCC reference strains |
Test Results & Analytical Data
| Test Parameter | Specification | Method | Result | Status |
|---|---|---|---|---|
| Appearance (powder) | Homogeneous; light beige to pale pink; no lumps | Visual inspection | Conforms | PASS |
| Appearance (prepared) | Opaque, red-brown gel; homogeneous; no contamination | Visual — plate check | Conforms | PASS |
| pH (prepared, 25 °C) | 7.1 – 7.5 | Potentiometry (ISO 10523) | 7.3 | PASS |
| Gel strength (prepared) | Firm gel; no syneresis or collapse | Visual — plate check | Firm | PASS |
| Loss on Drying | ≤ 7.0% w/w | 105 °C / 2 h (gravimetric) | 3.9% | PASS |
| Growth — H. pylori ATCC 43504 | Good growth; small translucent colonies at day 3–5 (37 °C, microaerophilic) | Microaerophilic culture | Good growth | PASS |
| Inhibition — E. coli ATCC 25922 | Complete / ≥ 99% inhibition (aerobic, 37 °C, 48 h) | Selectivity test | Complete | PASS |
| Inhibition — C. albicans ATCC 10231 | Complete inhibition | Antifungal selectivity | Complete | PASS |
| Haemolysis pattern | Gamma (non-haemolytic) for H. pylori | Visual — plate check | Gamma | PASS |
| Sterility (prepared medium) | No growth at 14 days (aerobic, 30–35 °C) | Incubation sterility check | No growth | PASS |
| Performance Compliance | Supports H. pylori growth; inhibits contaminants per specification | Performance review | Conforms | CONFORM |
Conclusion: Lot HPS260301 has been tested against all release specifications for H. pylori Selective Agar. Performance-verified using H. pylori ATCC 43504 under microaerophilic conditions. This lot is RELEASED for use.
Quality Control Analyst
AuSaMicS Quality Control Department
Date: March 2026 | Signature: _______________
Quality Manager
AuSaMicS Pty Ltd
Date: March 2026 | Signature: _______________
AuSaMicS Pty Ltd (ABN 56 676 640 467) warrants this product meets specifications at time of manufacture. For laboratory use only. Not intended for human, animal, food, feed, or pharmaceutical use. AuSaMicS Pty Ltd shall not be held liable for any damages resulting from use outside the intended application. · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au
AuSaMicS Pty Ltd · ABN 56 676 640 467 · 31 Longview CT, Thomastown VIC 3074, Australia · support@ausamics.com · +61 412 520 598 · www.ausamics.com.au